Preclinical studies indicate that SOT106 (anti-LRRC15 ADC) is highly effective and well-tolerated with significant promise for treating sarcomas and potentially other LRRC15-positive malignancies IND filing anticipated in Q4 2026 Program advancing towards clinical readiness and exploring partnering opportunities SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced favorable preclinical results supporting the development of SOT106, its antibody-drug...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by SOTIO Biotech
SOTIO Announces Promotion of Vivi Boura to Chief Medical Officer
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the promotion of Vivi Boura, M.D., Ph.D., an accomplished oncologist with extensive experience leading the clinical development of novel cancer therapies, to chief medical officer.
SOTIO to Present Data Highlighting Progress Across ADC and Immunocytokine Programs at Upcoming Scientific Conferences
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new preclinical and translational data from multiple investigational programs at two scientific conferences in November – the World ADC Conference in San Diego, California, and PEGS Europe, in Lisbon, Portugal.
SOTIO Strengthens Leadership Team with Appointments of Amy Jensen-Smith as Chief Scientific Officer and Ulrich Moebius as Chief Development Officer
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the appointments of two accomplished scientific executives to its leadership team to support the continued progress of SOTIO’s pipeline of novel antibody-drug conjugates and immunotherapies for difficult-to-treat solid tumors.
SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments | Financial News | myMotherLode.com
SOT109 (targeting cadherin-17) exhibits potent efficacy and a favorable safety profile in preclinical models of colorectal cancer; currently in IND-enabling stage with IND filing anticipated in 2026 SOT106 (targeting LRRC15) exhibits robust preclinical efficacy in mesenchymal tumors, including broad subset of sarcomas SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, this week presented preclinical data on two of its leading antibody-drug conjugate (ADC)...
SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline. The presentations will take place at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL from April 25-30, 2025.
SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113
Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option agreement with Synaffix B.V. (“Synaffix”), a Lonza company (SWX: LONN), to obtain a license to Synaffix’s technology to develop two bispecific antibody-drug conjugate (ADC) programs.
SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer
SOT109 leverages exatecan-based payload to produce potential best-in-class ADC for validated CDH17 target SOT109 expected to enter a first-in-human Phase 1 clinical trial in 2026 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17).
SOTIO Advances Colorectal Cancer ADC Program, SOT109, and Licenses Fully Human Antibodies from Biocytogen for Novel Tumor Target
SOT109 will leverage antibodies generated with Biocytogen’s proprietary RenMab™ platform as backbone of ADC for colorectal cancer and other gastrointestinal cancers SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced the licensing of fully human antibodies from Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics.
SOTIO Showcases New Data on SOT201 Immunocytokine, VICTORIA-01 Clinical Study, and BOXR CAR-T Advancements at 2024 SITC Annual Meeting
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced data supporting SOT201, its next-generation PD-1-targeting immunocytokine. The company also reported advancements in its BOXR cell therapy platform, introducing an innovative chimeric PGC-1α transgene to boost CAR T cell efficacy in patients with solid tumors.
SOTIO Announces Upcoming Poster Presentations at the 2024 SITC Annual Meeting
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November 6 - 10, 2024, in Houston, TX. Data to be presented include the investigation of a novel chimeric PGC-1α transgene to enhance CAR T cell efficacy in patients with solid tumors.
Chemotherapy drives tertiary lymphoid structures that correlate with ICI-responsive TCF1+CD8+ T cells in metastatic ovarian cancer
This content is only available via PDF. This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License .
SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline
Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform Agreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCs Biocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 million SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, and Biocytogen (HKEX: 02315), a global...
SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors
Novel immunocytokine utilizes dual mechanisms of action to activate immune system to fight solid tumors Company has received IND and CTA approval to initiate Phase 1 study in the U.S. and Europe SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced the dosing of the first patient in its Phase 1, first-in-human clinical trial evaluating SOT201, a next-generation PD-1-targeting immunocytokine.
SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting
Patient enrollment and dosing ongoing in first-in-human study of BOXR1030 enhanced CAR T-cell therapy SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present on June 1, 2024 (Developmental Therapeutics—Immunotherapy session) a Trial-in-Progress poster on the first-in-human DUET-01 Phase 1/2 study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024, in Chicago, IL. BOXR1030 is a next-generation GPC3-targeted CAR T-cell therapy enhanced with a transgene encoding GOT2, a critical enzyme involved in cellular metabolism.
SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California. In a poster at the conference, SOTIO will present data from the company’s BOXR platform of enhanced T cell therapies.
News
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California. In a poster at the conference, SOTIO will present data from the company's BOXR platform of enhanced T cell therapies.
SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California. Data to be presented include new preclinical results supporting the continued development of SOT201, a next-generation PD-1-inhibiting cytokine that SOTIO is progressing toward a planned first-in-human study in the second quarter of 2024.
SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology
SOTIO will leverage Synaffix’s antibody-drug conjugate platform for the design of up to three novel ADCs to address indications with high unmet medical need Collaboration bolsters SOTIO’s wider portfolio of differentiated immuno-oncology therapies tailored to address the specific challenges of solid tumors Synaffix will receive an upfront payment and potential development milestone payments totaling $740 million SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, today...
SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa
Ongoing clinical trials of nanrilkefusp alfa will be discontinued due to insufficient efficacy SOTIO plans to explore combinations of nanrilkefusp alfa with other modalities SOTIO to continue to advance its immunocytokine platform including next-generation SOT201 program SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will discontinue the currently ongoing clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab...
SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer
Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population Phase 1/2 study is evaluating SOT102, a Claudin 18.2 antibody-drug conjugate, for treatment of gastric and pancreatic cancers SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, announced today that it has dosed the first patients in the combination therapy arms of its Phase 1/2 CLAUDIO-01 trial.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with SOTIO
Contact SOTIO, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack